Paul N. Meyer

Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Nathalie A. Johnson, Graham W. Slack, Kerry J. Savage et al. · Journal of Clinical Oncology · 2012 · 954 citations

Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab

Paul N. Meyer, Kai Fu, Timothy C. Greiner et al. · Journal of Clinical Oncology · 2010 · 476 citations

BCL2 Predicts Survival in Germinal Center B-cell–like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab

Javeed Iqbal, Paul N. Meyer, Lynette M. Smith et al. · Clinical Cancer Research · 2011 · 174 citations · Full text

Xp11.2 Translocation Renal Cell Carcinoma With Very Aggressive Course in Five Adults

Paul N. Meyer, Joseph I. Clark, Robert C. Flanigan et al. · American Journal of Clinical Pathology · 2007 · 133 citations · Full text

Renal Pathology, Pathology, Very Aggressive Course +17

The Stromal Cell Marker SPARC Predicts for Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab

Paul N. Meyer, Kai Fu, Timothy C. Greiner et al. · American Journal of Clinical Pathology · 2010 · 82 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Cancer Immunosurveillance +14